SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for invasive fungal infections will be presented at the joint conference of the International Immunocompromised Host Society (ICHS) and INFOCUS Latinomérica from November 13-15, 2016 in Santiago, Chile. CD101 is Cidara’s lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class.
The ICHS and INFOCUS are prestigious annual events highlighting the latest developments related to infections in immunocompromised patients and fungal infections, respectively. They are hosting their meetings together for the first time to address the increasing incidence of fungal infections in immunocompromised patients.
CD101 data being presented at the joint ICHS/INFOCUS conference will include new results from preclinical studies evaluating subcutaneous administration of the compound, which represents a novel approach in antifungal treatment and prevention. This abstract was selected by the conference’s Scientific Committee as one of the top works of all that were submitted, a recognition that reflects the importance of and interest in this research. A second presentation will review data from two recently completed Phase 1 dose-escalation trials of CD101 IV that demonstrate the compound’s clinical pharmacokinetics, safety and tolerability. CD101 IV is currently being developed as a once-weekly treatment for invasive fungal infections.
“Cidara’s presence at this international forum demonstrates our commitment to broadening the dissemination of our scientific work in novel antifungal drug development and advancing new treatment options to support immunocompromised patients, who are at high risk of developing life-threatening fungal infections,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We look forward to engaging with this scientific community to share the latest results of our CD101 clinical research, including the exciting study investigating the potential to broaden utility for CD101 through availability of a subcutaneous injection.”
Titles and abstract numbers for the Cidara ICHS/INFOCUS poster presentations are as follows:
- 048: Subcutaneous (SC) Injection of CD101, a Novel Echinocandin: Efficacious, Well-Tolerated and Sustained Drug Exposures; V. Ong, et. al.
- 065: Safety and Pharmacokinetics of Single and Multiple Doses of CD101 IV: Results from Two Phase 1 Dose-Escalation Studies; T. Sandison, et. al.
Posters will be on display beginning Monday, November 14, 2016 at 10:00 a.m. through Tuesday, November 15, 2016 at 5:00 p.m., CLST. There are also two poster viewing times on Monday and Tuesday from 4:00 p.m. to 5:00 p.m., CLST.
Copies of these posters will be available on the Cidara website following the meeting: http://www.Cidara.com/
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101, through Phase 2 studies in two indications and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD101 topical is the first and only agent of its class being studied for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, long-acting nature, anticipated human dosing and other attributes of CD101 IV and CD101 subcutaneous, and their potential to treat infections. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.